BRAF and melanoma: Similar enhanced anti-tumor combination activity was observed in a BRAF mutant (A375.X1) and NRAS mutant (IPC-298) melanoma model, suggesting the potential for application of this combination strategy in other MAPK-dysregulated settings (S9 Fig).